Dr.Β AnasΒ Younes
MD (Doctor of Medicine)
Chief, Lymphoma Service β Hematologic Oncology
corporate_fareMemorial Sloan Kettering Cancer Center, New York
Anas Younes
MD (Doctor of Medicine)
Dr. Anas Younes is one of the world's most recognised hematologic oncologists, with over 25 years of experience in lymphoma care, translational research, and novel drug development. He served as Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, one of the world's leading cancer hospitals, where he helped accelerate new treatment options for patients with Hodgkin and non-Hodgkin lymphoma.
Dr. Younes is internationally known for his pivotal role in the clinical development of brentuximab vedotin, a CD30-targeted antibody-drug conjugate that transformed the treatment of relapsed and refractory Hodgkin lymphoma and CD30-positive T-cell lymphoma. His research also helped establish PD-1 checkpoint inhibitors as a meaningful option in relapsed classical Hodgkin lymphoma. Before joining Memorial Sloan Kettering Cancer Center in 2013, he spent approximately two decades at The University of Texas MD Anderson Cancer Center, where he led clinical investigation and translational research programmes in lymphoma and myeloma. He is one of the most cited lymphoma oncologists worldwide and has served as principal investigator in numerous pivotal lymphoma trials. He currently holds a senior global hematology research and development leadership role at AstraZeneca, contributing to the next generation of blood cancer therapies.
Why Consider Dr. Anas Younes?
Dr. Younes represents some of the most important advances in modern lymphoma treatment, with a career built on translational research, targeted therapy development, and expanding options for patients with difficult-to-treat lymphoma.
Areas of Specialisation
Expert lymphoma care with a focus on targeted therapy, immunotherapy, and novel agents for relapsed and refractory disease
Dr. Younes specialises in the full spectrum of lymphoid malignancies, with particular expertise in Hodgkin lymphoma, diffuse large B-cell lymphoma, T-cell lymphoma, and CD30-positive lymphomas. His clinical and research work integrates biomarker-driven treatment selection, antibody-drug conjugates, and immune checkpoint blockade.
Hodgkin Lymphoma
Classical and nodular lymphocyte-predominant Hodgkin lymphoma, including relapsed and refractory disease after standard therapy or stem cell transplant.
- arrow_rightTreatment strategies for disease recurring after ABVD or escalated BEACOPP
- arrow_rightEvaluation of options after autologous stem cell transplant failure
- arrow_rightBrentuximab vedotin-based therapy for eligible patients
- arrow_rightPD-1 inhibitor therapy for checkpoint-sensitive disease
- arrow_rightCD30 expression-guided treatment planning in Hodgkin lymphoma
- arrow_rightAntibody-drug conjugate protocols for relapsed CD30-positive disease
- arrow_rightCombination regimens incorporating targeted and immune agents
Non-Hodgkin Lymphoma
Diffuse large B-cell lymphoma, T-cell lymphoma, and other aggressive lymphoma subtypes, with emphasis on novel treatment strategies for patients who have relapsed or not responded to standard regimens.
- arrow_rightNovel agent evaluation for relapsed or refractory DLBCL
- arrow_rightBiomarker-directed treatment planning including molecular subtyping
- arrow_rightClinical trial access and early-phase treatment options
- arrow_rightSystemic anaplastic large cell lymphoma and peripheral T-cell lymphoma
- arrow_rightCD30-targeted therapy including brentuximab vedotin
- arrow_rightNovel combination approaches for aggressive T-cell subtypes
Immunotherapy and Novel Agents
Immune checkpoint inhibition, antibody-drug conjugates, and emerging targeted therapies in lymphoma, particularly for patients with limited options after multiple lines of treatment.
- arrow_rightPD-1 inhibitors including nivolumab and pembrolizumab in relapsed Hodgkin lymphoma
- arrow_rightImmune-based treatment for PD-L1/PD-L2-expressing lymphoma subtypes
- arrow_rightCombination immunotherapy strategies in appropriate clinical contexts
- arrow_rightBrentuximab vedotin for CD30-positive Hodgkin and T-cell lymphoma
- arrow_rightNext-generation ADC development and clinical investigation
Procedures and Clinical Services
Lymphoma diagnosis, targeted treatment planning, clinical trial access, and expert second opinion
Dr. Younes's clinical practice centres on the evaluation and management of complex and relapsed lymphoma, incorporating molecular diagnostics, novel targeted therapies, immunotherapy, and access to early-phase clinical investigations.
Lymphoma Diagnosis and Staging
DiagnosisComprehensive workup including biopsy evaluation, immunohistochemistry, molecular profiling, and staging assessment to guide precise treatment selection.
Targeted and Immune-Based Therapy
Targeted TherapyMolecularly guided treatment approaches incorporating CD30-targeted agents, checkpoint inhibitors, and next-generation lymphoma therapies.
Systemic Lymphoma Treatment
Medical OncologyMedical management of Hodgkin lymphoma, diffuse large B-cell lymphoma, T-cell lymphoma, and related hematologic malignancies.
Second Opinion and Complex Lymphoma Review
Second OpinionExpert review of complex, relapsed, or refractory lymphoma cases, providing an independent clinical perspective on diagnosis, staging, and treatment strategy.
Research and Publications
Landmark contributions to lymphoma drug development, antibody-drug conjugates, and checkpoint immunotherapy
Dr. Younes is one of the most cited lymphoma oncologists internationally, with a research career spanning targeted therapy, immune checkpoint blockade, antibody-drug conjugates, and biomarker-guided treatment strategies. His work has directly influenced the treatment of Hodgkin lymphoma, DLBCL, and T-cell lymphoma.
Dr. Younes's complete publication list is available on PubMed and Google Scholar. He is among the most cited lymphoma oncologists in the world, with contributions spanning more than two decades of lymphoma drug development.
Education & Training
Dr. Younes received his medical training in Syria before completing residency and fellowship training in the United States, including haematology-oncology fellowship at Memorial Sloan Kettering Cancer Center.
Clinical Experience
Dr. Younes has held senior clinical and research leadership positions at two of the world's most prominent cancer centres, spanning more than 25 years of dedicated lymphoma practice and drug development.
Languages & International
Dr. Anas Younes consults in the following languages.
Dr. Younes consults in both English and Arabic, making him directly accessible to patients from the Middle East, North Africa, and Arabic-speaking communities seeking expert lymphoma care at Memorial Sloan Kettering Cancer Center.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Anas Younes
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Anas Younes's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Anas Younes's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Anas Younes before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Anas Younes's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Anas Younes's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Anas Younes's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Anas Younes
Dr. Anas Younes is an internationally recognised hematologic oncologist and lymphoma researcher with over 25 years of experience. He is best known for his pivotal role in the clinical development of brentuximab vedotin, a CD30-targeted antibody-drug conjugate, and for his contributions to PD-1 checkpoint inhibitor research in relapsed classical Hodgkin lymphoma. He formerly served as Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York.
Dr. Younes specialises in lymphoid malignancies, with primary expertise in classical Hodgkin lymphoma, diffuse large B-cell lymphoma, T-cell lymphoma, and CD30-positive lymphomas including systemic anaplastic large-cell lymphoma. His research and clinical focus are especially relevant for patients with relapsed or refractory disease who require targeted or immune-based therapy.
A second-opinion request can be submitted through CancerFax with the patient's complete pathology reports, imaging, treatment history, and relevant laboratory results. The CancerFax team will review the documents and coordinate the case submission to Memorial Sloan Kettering Cancer Center. The consultation format and timeline depend on the doctor's availability and hospital acceptance criteria.
Memorial Sloan Kettering Cancer Center has an established international patient programme. CancerFax can coordinate the process for international patients seeking a review or consultation, including case preparation, report translation support, and communication with the hospital's international team. Acceptance is subject to case suitability and the hospital's availability.
Brentuximab vedotin is an antibody-drug conjugate that targets the CD30 protein expressed in classical Hodgkin lymphoma and some T-cell lymphomas. Dr. Younes played a central role in the clinical development of this therapy, including leading or contributing to pivotal clinical trials that led to its approval. Brentuximab vedotin is now a standard treatment option for relapsed or refractory CD30-positive lymphoma.
Yes. Dr. Anas Younes consults in both English and Arabic. This makes him directly accessible to patients from the Middle East, North Africa, and other Arabic-speaking communities who are seeking expert lymphoma guidance or a second opinion from one of the world's leading lymphoma specialists.
Connect with Anas Younes Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.